Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

CorMedix (CRMD) Net Margin (2016 - 2025)

CorMedix has reported Net Margin over the past 12 years, most recently at 10.9% for Q4 2025.

  • Quarterly results put Net Margin at 10.9% for Q4 2025, down 9333.0% from a year ago — trailing twelve months through Dec 2025 was 52.95% (up 5034.0% YoY), and the annual figure for FY2025 was 52.31%, up 4970.0%.
  • Net Margin reached 10.9% in Q4 2025 per CRMD's latest filing, down from 104.08% in the prior quarter.
  • Across five years, Net Margin topped out at 91671.03% in Q1 2022 and bottomed at 100538.67% in Q3 2022.
  • Median Net Margin over the past 4 years was 55.0% (2025), compared with a mean of 4503.76%.
  • Peak annual rise in Net Margin hit 8351341bps in 2022, while the deepest fall reached -12311796bps in 2022.
  • Over 4 years, Net Margin stood at 17141.29% in 2021, then crashed by -61bps to 27637.7% in 2022, then skyrocketed by 100bps to 104.23% in 2024, then crashed by -90bps to 10.9% in 2025.
  • Business Quant data shows Net Margin for CRMD at 10.9% in Q4 2025, 104.08% in Q3 2025, and 55.0% in Q2 2025.